加服阿托伐他汀后不稳定型心绞痛患者血脂和血清超敏C-反应蛋白水平的观察  

Observation of lipid and serum high sensitive C-reactive protein levels for patients with unstable angina after taking Atorvastatin

作　　者：张金芳[1] 刘英[1] 吴迪[1] 马丽媛[1] 

机构地区：[1]大连市第二人民医院心内科,辽宁大连116011

出　　处：《中国民康医学》2014年第21期25-26,75,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察阿托伐他汀对不稳定型心绞痛患者血脂和血管炎性反应的影响。方法:64例不稳定型心绞痛患者分为常规治疗组和阿托伐他汀组,两组患者均予常规对症支持治疗,阿托伐他汀组患者在此基础上加服阿托伐他汀20mg,1次/晚,共8周。结果:阿托伐他汀组患者治疗前后的血脂水平变化及血清超敏C-反应蛋白水平变化差异有统计学意义(P<0.05)。阿托伐他汀组患者血脂水平改善优于常规治疗组(P<0.05),血清超敏C-反应蛋白水平低于常规治疗组(P<0.05)。两组患者治疗期间未见明显不良反应发生。结论:阿托伐他汀治疗不稳定型心绞痛可明显降低血脂及减轻血管炎症反应。Objective：To observe effects of Atorvastatin on lipids and vascular inflammatory reactions in patients with unstable angina. Methods：64 patients with unstable angina patients were divided into conventional treatment group and Atorvastatin group. The two groups herein were given conventional symptomatic and supportive treatment, besides that, Atorvastatin group took atorvastatin 20 mg once per night for a total of eight weeks. Results：There were statistical differences in the lipid level and serum high sensitive C pro-tein level for Atorvastatin group before and after the treatment （P〈0. 05）. The improvement of the lipid level of Atorvastatin group was better than that of conventional treatment group （P〈0. 05）, and the serum high sensitive C protein level of Atorvastatin group was low-er than that of conventional treatment group （P〈0. 05）. For the two groups, no significant adverse reactions occurred during the treat-ment. Conclusions：Atorvastatin treatment of unstable angina can significantly reduce blood lipids and reduce vascular inflammatory re-actions.

关 键 词：阿托伐他汀 不稳定型心绞痛 超敏C-反应蛋白 血脂 

分 类 号：R541.4[医药卫生—心血管疾病]